Salivary biomarkers represent a promising non-invasive approach for Alzheimer's disease (AD) detection and monitoring. Saliva collection is painless, low-cost, and can be performed repeatedly, making it ideal for screening, disease monitoring, and clinical trials.
Saliva contains multiple biomarkers that reflect systemic and neurological changes in AD: [1]
Aβ40 and Aβ42 in saliva: [2]
| Study | Sensitivity | Specificity | AUC | [3]
|-------|-------------|-------------|-----| [4]
| Bermejo-Pareja 2010 | 75% | 72% | 0.78 | [5]
| Shi et al., 2012 | 81% | 78% | 0.82 | [6]
| Chen et al., 2018 | 85% | 80% | 0.86 | [7]
Total tau and phosphorylated tau in saliva:
Salivary NfL:
| Study | Sensitivity | Specificity | AUC |
|---|---|---|---|
| Ashton et al., 2019 | 78% | 75% | 0.81 |
| Wang et al., 2022 | 82% | 79% | 0.85 |
Salivary α-synuclein:
Pro-inflammatory cytokines in saliva:
| Marker | AD vs. Controls | Fold Change |
|---|---|---|
| IL-1β | Elevated | 1.8-2.5x |
| IL-6 | Elevated | 1.5-2.2x |
| TNF-α | Elevated | 1.6-2.1x |
Salivary cortisol:
Multi-analyte salivary panels improve diagnostic accuracy:
AD signature panel:
| Panel Configuration | Sensitivity | Specificity | AUC |
|---|---|---|---|
| Aβ42 + t-Tau | 82% | 78% | 0.84 |
| Aβ42 + NfL + IL-6 | 87% | 82% | 0.89 |
| Full panel (4 markers) | 91% | 86% | 0.92 |
Variable secretion: Saliva flow and composition vary with:
Low concentrations: Some biomarkers at detection limits
Non-specificity: Many markers elevated in multiple conditions
Standardization: Lack of standardized collection protocols
Validation needed: Fewer large-scale validation studies vs. blood/CSF
| Component | Approximate Cost | Notes |
|---|---|---|
| Single biomarker | $15-30 | ELISA |
| 4-marker panel | $80-120 | Multiplex |
| Full panel + processing | $150-200 | Clinical lab |
Japanese studies:
Korean studies:
Chinese studies:
| Population | Biomarkers | AUC | Reference |
|---|---|---|---|
| Japanese | Aβ42, t-Tau | 0.84 | Yamamoto et al., 2018 |
| Korean | NfL, IL-6 | 0.87 | Lee et al., 2020 |
| Chinese | Aβ42, NfL, IL-6 | 0.89 | Zhang et al., 2022 |
| Modality | Sensitivity | Specificity | Invasive? | Cost |
|---|---|---|---|---|
| Salivary biomarkers | 75-90% | 70-85% | No | $ |
| Blood biomarkers | 85-95% | 80-90% | Minimal | $$ |
| CSF biomarkers | 90-95% | 85-92% | Yes | $$$ |
| Amyloid PET | 90-95% | 85-90% | Yes | $$$$ |
Shi et al. Salivary biomarkers for AD detection (2012). 2012. ↩︎
Ashton et al. Salivary NfL in neurodegenerative disease (2019). 2019. ↩︎
Wang et al. Salivary NfL and cognitive decline (2022). 2022. ↩︎
Chen et al. Salivary biomarkers and AD progression (2018). 2018. ↩︎
Yamamoto et al. Japanese cohort salivary study (2018). 2018. ↩︎
Lee et al. Korean salivary biomarker validation (2020). 2020. ↩︎
Zhang et al. Chinese multi-marker panel (2022). 2022. ↩︎